You are here: Industry Insights > Biogen

News List

Biogen launches digital self-help tool to support mental health in MS pharmatimes
June 05, 2020
Biogen has announced the UK launch of a new digital self-help tool to support the mental health of people with multiple sclerosis.
Biogen, Vir Enter COVID-19 Antibody Alliance contractpharma
March 16, 2020
Biogen will provide cell line development, process development and clinical manufacturing for Vir's monoclonal antibodies.
Biogen, Sangamo team up on neurological diseases pharmatimes
March 06, 2020
Biogen and Sangamo have unveiled plans to collaborate on a new global licensing agreement to develop and commercialise ST-501 for tauopathies including Alzheimer’s disease, and other neurological diseases.
Biogen and Sangamo to develop neurological disease drugs pharmaceutical-technology
March 03, 2020
Biogen and Sangamo Therapeutics have signed a global licensing agreement for the development of drugs to treat neurological diseases, including Alzheimer’s and Parkinson’s diseases.
Ionis Licenses Investigational Alzheimer's Therapy americanpharmaceuticalreview
December 23, 2019
Ionis Pharmaceuticals announced Biogen, a collaboration partner for neurological diseases, has licensed IONIS-MAPTRx, an antisense therapy designed to selectively reduce production ...
CHMP recommends Biogen’s Plegridy and Avonex use in pregnancy pharmaceutical-technology
September 26, 2019
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the use of interferon beta therapies, including Biogen’s Plegridy and Avonex ...
Eisai, Biogen to Discontinue Elenbecestat Study americanpharmaceuticalreview
September 17, 2019
Eisai and Biogen announced the decision to discontinue the Phase III clinical studies (MISSION AD1, AD2) on the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code ...
Eisai, Biogen discontinue clinical studies on AD drug candidate biospectrumasia
September 16, 2019
The accumulation and aggregation of A beta in the brain plays A key role in the pathogenesis of AD. The subtypes of ApoE affect the metabolism, accumulation and deposition of A beta to different degrees.
Biogen and Invitae to Offer Genetic Testing Program for Spinal Muscular Atrophy (SMA) to Improve Speed of Diagnosis for Patients americanpharmaceuticalreview
August 21, 2019
Biogen Inc. and Invitae Corporation have announced that SMA STAT, a new, rapid-turnaround genetic test for spinal muscular atrophy (SMA), will be offered at no charge to individuals in the U.S. as part of the SMA Identified program.
Fujifilm pays Biogen nearly $1B for Denmark biologics site fiercepharma
August 13, 2019
Fujifilm has sealed the deal. With the completion of an $890 million, all-cash exchange with Biogen, the CDMO is now in possession of a biologics production facility in Denmark with about 800 employees.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page